CA19-9 Cancer Antigen

Added to your cart

CA19-9 Cancer Antigen

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P291-4


Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

CA19-9 is elevated in blood, primarily in patients with carcinoma of the gastro-intestinal tract. Higher levels are more likely to be due to malignancy than lower levels, however very high levels are occasionally seen in patients with benign conditions such as cirrhosis. CA19-9 is not sufficiently specific for use as a screening test, its greatest usefulness is with pancreatic cancer compared with pancreatitis. The specificity for pancreatic cancer increases with increasing levels, high levels showing a specificity of >97%.


More information



  • Shipping Information
  • Dry Ice
  • Abbreviations
  • CA19-9
  • Specification
  • > 100 Ku/ml CA19-9
  • Recommended Use
  • Research and further manufacturing
  • Preservatives
  • 0.09% NaN3
  • Buffer
  • 0.05M sodium phosphate buffer, pH 7.5 containing 1M NaCl
  • Presentation Matrix
  • 0.05M phosphate buffer, pH 7.5 containing 1M NaCl and 0.09% NaN3
  • Purity/grade
  • Low Cross Contamination
  • Source
  • Human Cell Line
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • 210kDa

Technical Documents

Certificates Of Analysis (82.48KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox